These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33126941)

  • 21. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
    Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
    Akkerman O; Aleksa A; Alffenaar JW; Al-Marzouqi NH; Arias-Guillén M; Belilovski E; Bernal E; Boeree MJ; Borisov SE; Bruchfeld J; Cadiñanos Loidi J; Cai Q; Caminero JA; Cebrian Gallardo JJ; Centis R; Codecasa LR; D'Ambrosio L; Dalcolmo M; Danila E; Dara M; Davidavičienė E; Davies Forsman L; De Los Rios Jefe J; Denholm J; Duarte R; Elamin SE; Ferrarese M; Filippov A; Ganatra S; Garcia A; García-García JM; Gayoso R; Giraldo Montoya AM; Gomez Rosso RG; Gualano G; Hoefsloot W; Ilievska-Poposka B; Jonsson J; Khimova E; Kuksa L; Kunst H; Laniado-Laborín R; Li Y; Magis-Escurra C; Manfrin V; Manga S; Marchese V; Martínez Robles E; Maryandyshev A; Matteelli A; Migliori GB; Mullerpattan JB; Munoz-Torrico M; Mustafa Hamdan H; Nieto Marcos M; Noordin NM; Palmero DJ; Palmieri F; Payen MC; Piubello A; Pontali E; Pontarelli A; Quirós S; Rendon A; Skrahina A; Šmite A; Solovic I; Sotgiu G; Souleymane MB; Spanevello A; Stošić M; Tadolini M; Tiberi S; Udwadia ZF; van den Boom M; Vescovo M; Viggiani P; Visca D; Zhurkin D; Zignol M;
    Int J Infect Dis; 2019 Jun; 83():72-76. PubMed ID: 30953827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea.
    Taune M; Ustero P; Hiashiri S; Huang K; Aia P; Morris L; Main S; Chan G; du Cros P; Majumdar SS
    Public Health Action; 2019 Sep; 9(Suppl 1):S73-S79. PubMed ID: 31579654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
    Udwadia ZF; Amale RA; Mullerpattan JB
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedaquiline for multidrug-resistant TB in paediatric patients.
    Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
    Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries.
    Fekadu G; Yao J; You JHS
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):897-910. PubMed ID: 33931005
    [No Abstract]   [Full Text] [Related]  

  • 37. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.
    Vambe D; Kay AW; Furin J; Howard AA; Dlamini T; Dlamini N; Shabangu A; Hassen F; Masuku S; Maha O; Wawa C; Mafukidze A; Altaye K; Sikhondze W; Gwitima T; Keus K; Simelane T; Kerschberger B
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1095-1102. PubMed ID: 33126945
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.